Today is Rare Disease Day, an annual event that raises awareness about rare diseases at a national and global level.

As part of Nutra Pharma’s ongoing effort to help raise awareness about rare diseases, we would like to take the opportunity to share with you a couple important organizations that are making great strides in rare disease collaboration and outreach.

Over the past few years, we have continued to proudly support RareShare, an organization co-founded in 2008 by our Chief Marketing Officer, David Isserman. RareShare was created as a free online community designed to connect people affected by rare medical disorders, including those diagnosed with Adrenomyeloneuropathy (AMN), a rare disease for which Nutra Pharma has continued to work towards developing a treatment. Today, RareShare hosts over 3,000 members worldwide and is continuing to expand and grow its membership base.

More recently, we joined The Global Genes Project as a corporate supporter. The Global Genes Project recently launched as part of a worldwide effort to increase awareness for the prevalence of rare diseases and help those affected by them. It is the hope of The Global Genes Project organizers and supporters that the rare disease community, as a whole, will view this initiative as an opportunity to build unity around this important cause.

It is important to remember that while individual rare diseases seem to impact only a small portion of the population, together they affect over 30 million people in the United States and Europe. For this reason, we hope that you will take a moment to review both RareShare and The Global Genes Project and share these links with others you know, so that those affected by rare diseases will know that hope and support exist and that they have not been forgotten.

SEC Disclaimer
This article contains forward-looking statements. The words or phrases "would be," "will allow," "intends to," "will likely result," "are expected to," "will continue," "is anticipated," "estimate," "project," or similar expressions are intended to identify "forward-looking statements." Actual results could differ materially from those projected in Nutra Pharma's ("the Company") business plan. The Company's business is subject to various risks, which are discussed in the Company's filings with the Securities and Exchange Commission ("SEC"). The above article, " Recognizing Rare Disease Day 2010", should not be construed as an indication in any way whatsoever of: (a) the Company’s financial value; and/or (b) any predictive value of the Company’s future stock price. The Company's filings may be accessed at the SEC's Edgar system at www.sec.gov. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company cautions readers not to place reliance on such statements. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.

               

Comments

No comments yet.

RSS feed for comments on this post.

TrackBack URL

Leave a Comment

Name (required)

Email (will not be published) (required)

Website